Summary
Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H2 2016’, provides an overview of the Alzheimer's Disease pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects
- The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
lzheimer's Disease - Companies Involved in Therapeutics Development
AB Science SA
AbbVie Inc
AC Immune SA
Accera, Inc.
Acelot, Inc.
Actinogen Limited
Acumen Pharmaceuticals, Inc.
Addex Therapeutics Ltd
Affibody AB
AFFiRiS AG
Alector LLC
Alkermes Plc
Allergan Plc
Allinky Biopharma
ALSP, Inc.
Alzhyme Pty Ltd
Alzinova AB
AlzProtect SAS
Amarantus Bioscience Holdings, Inc.
Amgen Inc.
Anavex Life Sciences Corp.
Aphios Corporation
Apodemus AB
Applied Research using OMIC Sciences, S.L.
Araclon Biotech, S.L.
Archer Pharmaceuticals, Inc.
ArmaGen Inc.
Artery Therapeutics, Inc.
AskAt Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
Ausio Pharmaceuticals, LLC
Avineuro Pharmaceuticals, Inc.
Axon Neuroscience SE
Axovant Sciences Ltd.
Axsome Therapeutics, Inc.
Axxam SpA
Beactica AB
Berg LLC
BioArctic Neuroscience AB
Bioasis Technologies Inc.
Biogen Inc
Biomar Microbial Technologies
Bionature E.A. Ltd.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Bsim2
Cardax Pharmaceuticals, Inc.
Carna Biosciences, Inc.
Celon Pharma Sp. z o.o.
CHA Bio & Diostech Co., Ltd.
Chase Pharmaceuticals Corporation
Clera Inc.
Cognition Therapeutics, Inc.
Cognosci, Inc.
CohBar, Inc.
Connexios Life Sciences Pvt. Ltd.
ContraVir Pharmaceuticals, Inc.
Corium International, Inc.
Coronis Partners Ltd.
Cortice Biosciences, Inc.
Critical Outcome Technologies Inc.
Crossbeta Biosciences B.V.
D-Pharm Ltd.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Daval International Limited
DermaXon, LLC
Dongkook Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Eli Lilly and Company
Emergent BioSolutions Inc.
EncephRx, Inc.
Endece, LLC
ENKAM Pharmaceuticals A/S
Ensemble Therapeutics Corporation
Ensol Biosciences Inc.
Epigen Biosciences, Inc.
Euroscreen S.A.
Evotec AG
F. Hoffmann-La Roche Ltd.
FORUM Pharmaceuticals Inc.
Genentech, Inc.
Genervon Biopharmaceuticals, LLC
GlaxoSmithKline Plc
GliaCure Inc.
Glialogix, Inc.
Golden Biotechnology Corp.
Grifols, S.A.
H. Lundbeck A/S
Heptares Therapeutics Limited
HitGen LTD
Humanetics Corporation
Ichor Medical Systems, Inc.
Icure Pharmaceutical Inc.
Immungenetics AG
Impel NeuroPharma, Inc.
ImStar Therapeutics Inc.
Inovio Pharmaceuticals, Inc.
IntelGenx Corp.
Intellect Neurosciences, Inc.
Intra-Cellular Therapies, Inc.
INVENT Pharmaceuticals, Inc.
Io Therapeutics, Inc.
Iproteos S.L.
Jeil Pharmaceutical Co., Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
K-Stemcell Co., Ltd.
Kadmon Corporation, LLC
Kalgene Pharmaceuticals Inc.
Kareus Therapeutics, SA
KineMed, Inc.
Krenitsky Pharmaceuticals Inc.
Kyowa Hakko Kirin Co., Ltd.
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lipopharma Therapeutics SL
Living Cell Technologies Limited
Lupin Limited
M3 Biotechnology, Inc.
ManRos Therapeutics
MedDay SA
Medestea Research & Production S.p.A.
MedImmune, LLC
Medisyn Technologies, Inc.
MEDRx Co., Ltd.
Merck & Co., Inc.
Metabolic Solutions Development Company, LLC
Mithridion, Inc.
Mitochon Pharmaceuticals, Inc.
NAL Pharmaceuticals Ltd.
Nanomerics Ltd
Nanotherapeutics, Inc.
Neuralstem, Inc.
Neuraltus Pharmaceuticals, Inc.
Neurim Pharmaceuticals Ltd
Neuro-Sys SAS
Neurodyn Inc.
NeuroGeneration, Inc.
NeuroGenetic Pharmaceuticals, Inc.
NeuroNascent, Inc.
Neuronax SAS
NeurOp, Inc
NeuroPhage Pharmaceuticals, Inc.
Neuropore Therapies, Inc.
Neurotez, Inc.
New World Laboratories, Inc.
nLife Therapeutics, S.L.
NLS Pharma Group
Novartis AG
NsGene A/S
Oligomerix, inc.
ORPHIT
Oryzon Genomics SA
Otsuka Holdings Co., Ltd.
P2D Bioscience
Pain Therapeutics, Inc.
Palumed S.A.
Panacea Pharmaceuticals, Inc.
PeptiDream Inc.
Peptron, Inc.
Pfizer Inc.
PharmaKure Limited
PharmatrophiX, Inc.
Pharmaxis Limited
Pharnext SA
Phenomenome Discoveries, Inc.
Pivot Pharmaceuticals Inc
Prevacus, Inc.
Probiodrug AG
Progenra, Inc.
ProMIS Neurosciences Inc.
ProQR Therapeutics N.V.
Proteome Sciences Plc
Proteostasis Therapeutics, Inc.
QR Pharma, Inc.
Radius Health, Inc.
Regenera Pharma Ltd.
reMYND NV
Resverlogix Corp.
Retrotope, Inc
ReXceptor Inc.
Rodos BioTarget GmbH
Sage Therapeutics, Inc.
SanBio, Inc.
Saneron CCEL Therapeutics, Inc.
Saniona AB
Sanofi
Selvita S.A.
SeneXta Therapeutics SA
Serometrix, LLC
SignPath Pharma Inc
Signum Biosciences, Inc.
Simcere Pharmaceutical Group
SK Biopharmaceuticals Co., Ltd.
SOM Innovation Biotech SL
Spectrum Pharmaceuticals, Inc.
Stemedica Cell Technologies, Inc.
Sumitomo Dainippon Pharma Co., Ltd.
Summit Therapeutics Plc
Suven Life Sciences Ltd.
T3D Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
TauRx Therapeutics Ltd.
TechnologieAllianz e. V.
TechnoPhage SA
Teijin Pharma Limited
Teikoku Pharma USA, Inc.
Tetra Discovery Partners LLC
Thera Neuropharma Inc
Therapix Biosciences Ltd
Tiziana Life Sciences Plc
Toyama Chemical Co., Ltd.
Transition Therapeutics Inc.
Treventis Corporation
TyrNovo Ltd.
UCB S.A.
Varinel, Inc.
Vaxine Pty Ltd
Virobay Inc.
Vitae Pharmaceuticals, Inc.
Voyager Therapeutics, Inc.
vTv Therapeutics Inc
Vybion, Inc.
Wellstat Therapeutics Corporation
Zhejiang Hisun Pharmaceutical Co., Ltd.
'
Table of Contents
Table of Contents 2
Introduction 12
Alzheimer's Disease Overview 13
Therapeutics Development 14
Alzheimer's Disease - Therapeutics under Development by Companies 16
Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 37
Alzheimer's Disease - Pipeline Products Glance 44
Alzheimer's Disease - Products under Development by Companies 48
Alzheimer's Disease - Products under Investigation by Universities/Institutes 78
Alzheimer's Disease - Companies Involved in Therapeutics Development 88
Alzheimer's Disease - Therapeutics Assessment 316
Drug Profiles 372
Alzheimer's Disease - Dormant Projects 1152
Alzheimer's Disease - Discontinued Products 1199
Alzheimer's Disease - Product Development Milestones 1209
Appendix 1221
List of Tables
Number of Products under Development for Alzheimer's Disease, H2 2016 76
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H2 2016 77
Number of Products under Development by Companies, H2 2016 79
Number of Products under Development by Companies, H2 2016 (Contd..1) 80
Number of Products under Development by Companies, H2 2016 (Contd..2) 81
Number of Products under Development by Companies, H2 2016 (Contd..3) 82
Number of Products under Development by Companies, H2 2016 (Contd..4) 83
Number of Products under Development by Companies, H2 2016 (Contd..5) 84
Number of Products under Development by Companies, H2 2016 (Contd..6) 85
Number of Products under Development by Companies, H2 2016 (Contd..7) 86
Number of Products under Development by Companies, H2 2016 (Contd..8) 87
Number of Products under Development by Companies, H2 2016 (Contd..9) 88
Number of Products under Development by Companies, H2 2016 (Contd..10) 89
Number of Products under Development by Companies, H2 2016 (Contd..11) 90
Number of Products under Development by Companies, H2 2016 (Contd..12) 91
Number of Products under Development by Companies, H2 2016 (Contd..13) 92
Number of Products under Development by Companies, H2 2016 (Contd..14) 93
Number of Products under Development by Companies, H2 2016 (Contd..15) 94
Number of Products under Development by Companies, H2 2016 (Contd..16) 95
Number of Products under Development by Companies, H2 2016 (Contd..17) 96
Number of Products under Development by Companies, H2 2016 (Contd..18) 97
Number of Products under Development by Companies, H2 2016 (Contd..19) 98
Number of Products under Investigation by Universities/Institutes, H2 2016 99
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 100
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 101
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 102
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 103
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 104
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 105
Comparative Analysis by Late Stage Development, H2 2016 106
Comparative Analysis by Clinical Stage Development, H2 2016 107
Comparative Analysis by Early Stage Development, H2 2016 108
Comparative Analysis by Unknown Stage Development, H2 2016 109
Products under Development by Companies, H2 2016 110
Products under Development by Companies, H2 2016 (Contd..1) 111
Products under Development by Companies, H2 2016 (Contd..2) 112
Products under Development by Companies, H2 2016 (Contd..3) 113
Products under Development by Companies, H2 2016 (Contd..4) 114
Products under Development by Companies, H2 2016 (Contd..5) 115
Products under Development by Companies, H2 2016 (Contd..6) 116
Products under Development by Companies, H2 2016 (Contd..7) 117
Products under Development by Companies, H2 2016 (Contd..8) 118
Products under Development by Companies, H2 2016 (Contd..9) 119
Products under Development by Companies, H2 2016 (Contd..10) 120
Products under Development by Companies, H2 2016 (Contd..11) 121
Products under Development by Companies, H2 2016 (Contd..12) 122
Products under Development by Companies, H2 2016 (Contd..13) 123
Products under Development by Companies, H2 2016 (Contd..14) 124
Products under Development by Companies, H2 2016 (Contd..15) 125
Products under Development by Companies, H2 2016 (Contd..16) 126
Products under Development by Companies, H2 2016 (Contd..17) 127
Products under Development by Companies, H2 2016 (Contd..18) 128
Products under Development by Companies, H2 2016 (Contd..19) 129
Products under Development by Companies, H2 2016 (Contd..20) 130
Products under Development by Companies, H2 2016 (Contd..21) 131
Products under Development by Companies, H2 2016 (Contd..22) 132
Products under Development by Companies, H2 2016 (Contd..23) 133
Products under Development by Companies, H2 2016 (Contd..24) 134
Products under Development by Companies, H2 2016 (Contd..25) 135
Products under Development by Companies, H2 2016 (Contd..26) 136
Products under Development by Companies, H2 2016 (Contd..27) 137
Products under Development by Companies, H2 2016 (Contd..28) 138
Products under Development by Companies, H2 2016 (Contd..29) 139
Products under Investigation by Universities/Institutes, H2 2016 140
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 141
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 142
Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 143
Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 144
Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 145
Products under Investigation by Universities/Institutes, H2 2016 (Contd..6) 146
Products under Investigation by Universities/Institutes, H2 2016 (Contd..7) 147
Products under Investigation by Universities/Institutes, H2 2016 (Contd..8) 148
Products under Investigation by Universities/Institutes, H2 2016 (Contd..9) 149
Alzheimer's Disease - Pipeline by AB Science SA, H2 2016 150
Alzheimer's Disease - Pipeline by AbbVie Inc, H2 2016 151
Alzheimer's Disease - Pipeline by AC Immune SA, H2 2016 152
Alzheimer's Disease - Pipeline by Accera, Inc., H2 2016 153
Alzheimer's Disease - Pipeline by Acelot, Inc., H2 2016 154
Alzheimer's Disease - Pipeline by Actinogen Limited, H2 2016 155
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals, Inc., H2 2016 156
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H2 2016 157
Alzheimer's Disease - Pipeline by Affibody AB, H2 2016 158
Alzheimer's Disease - Pipeline by AFFiRiS AG, H2 2016 159
Alzheimer's Disease - Pipeline by Alector LLC, H2 2016 160
Alzheimer's Disease - Pipeline by Alkermes Plc, H2 2016 161
Alzheimer's Disease - Pipeline by Allergan Plc, H2 2016 162
Alzheimer's Disease - Pipeline by Allinky Biopharma, H2 2016 163
Alzheimer's Disease - Pipeline by ALSP, Inc., H2 2016 164
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H2 2016 165
Alzheimer's Disease - Pipeline by Alzinova AB, H2 2016 166
Alzheimer's Disease - Pipeline by AlzProtect SAS, H2 2016 167
Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 168
Alzheimer's Disease - Pipeline by Amgen Inc., H2 2016 169
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp., H2 2016 170
Alzheimer's Disease - Pipeline by Aphios Corporation, H2 2016 171
Alzheimer's Disease - Pipeline by Apodemus AB, H2 2016 172
Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences, S.L., H2 2016 173
Alzheimer's Disease - Pipeline by Araclon Biotech, S.L., H2 2016 174
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals, Inc., H2 2016 175
Alzheimer's Disease - Pipeline by ArmaGen Inc., H2 2016 176
Alzheimer's Disease - Pipeline by Artery Therapeutics, Inc., H2 2016 177
Alzheimer's Disease - Pipeline by AskAt Inc., H2 2016 178
Alzheimer's Disease - Pipeline by Astellas Pharma Inc., H2 2016 179
Alzheimer's Disease - Pipeline by AstraZeneca Plc, H2 2016 180
Alzheimer's Disease - Pipeline by Asubio Pharma Co., Ltd., H2 2016 181
Alzheimer's Disease - Pipeline by Ausio Pharmaceuticals, LLC, H2 2016 182
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2016 183
Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H2 2016 184
Alzheimer's Disease - Pipeline by Axovant Sciences Ltd., H2 2016 185
Alzheimer's Disease - Pipeline by Axsome Therapeutics, Inc., H2 2016 186
Alzheimer's Disease - Pipeline by Axxam SpA, H2 2016 187
Alzheimer's Disease - Pipeline by Beactica AB, H2 2016 188
Alzheimer's Disease - Pipeline by Berg LLC, H2 2016 189
Alzheimer's Disease - Pipeline by BioArctic Neuroscience AB, H2 2016 190
Alzheimer's Disease - Pipeline by Bioasis Technologies Inc., H2 2016 191
Alzheimer's Disease - Pipeline by Biogen Inc, H2 2016 192
Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H2 2016 193
Alzheimer's Disease - Pipeline by Bionature E.A. Ltd., H2 2016 194
Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016 195
Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H2 2016 196
Alzheimer's Disease - Pipeline by Bsim2, H2 2016 197
Alzheimer's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H2 2016 198
Alzheimer's Disease - Pipeline by Carna Biosciences, Inc., H2 2016 199
Alzheimer's Disease - Pipeline by Celon Pharma Sp. z o.o., H2 2016 200
Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2016 201
Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016 202
Alzheimer's Disease - Pipeline by Clera Inc., H2 2016 203
Alzheimer's Disease - Pipeline by Cognition Therapeutics, Inc., H2 2016 204
Alzheimer's Disease - Pipeline by Cognosci, Inc., H2 2016 205
Alzheimer's Disease - Pipeline by CohBar, Inc., H2 2016 206
Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 207
Alzheimer's Disease - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016 208
Alzheimer's Disease - Pipeline by Corium International, Inc., H2 2016 209
Alzheimer's Disease - Pipeline by Coronis Partners Ltd., H2 2016 210
Alzheimer's Disease - Pipeline by Cortice Biosciences, Inc., H2 2016 211
Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc., H2 2016 212
Alzheimer's Disease - Pipeline by Crossbeta Biosciences B.V., H2 2016 213
Alzheimer's Disease - Pipeline by D-Pharm Ltd., H2 2016 214
Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 215
Alzheimer's Disease - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 216
Alzheimer's Disease - Pipeline by Daval International Limited, H2 2016 217
Alzheimer's Disease - Pipeline by DermaXon, LLC, H2 2016 218
Alzheimer's Disease - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016 219
Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016 220
Alzheimer's Disease - Pipeline by Eli Lilly and Company, H2 2016 221
Alzheimer's Disease - Pipeline by Emergent BioSolutions Inc., H2 2016 222
Alzheimer's Disease - Pipeline by EncephRx, Inc., H2 2016 223
Alzheimer's Disease - Pipeline by Endece, LLC, H2 2016 224
Alzheimer's Disease - Pipeline by ENKAM Pharmaceuticals A/S, H2 2016 225
Alzheimer's Disease - Pipeline by Ensemble Therapeutics Corporation, H2 2016 226
Alzheimer's Disease - Pipeline by Ensol Biosciences Inc., H2 2016 227
Alzheimer's Disease - Pipeline by Epigen Biosciences, Inc., H2 2016 228
Alzheimer's Disease - Pipeline by Euroscreen S.A., H2 2016 229
Alzheimer's Disease - Pipeline by Evotec AG, H2 2016 230
Alzheimer's Disease - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 231
Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc., H2 2016 232
Alzheimer's Disease - Pipeline by Genentech, Inc., H2 2016 233
Alzheimer's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2016 234
Alzheimer's Disease - Pipeline by GlaxoSmithKline Plc, H2 2016 235
Alzheimer's Disease - Pipeline by GliaCure Inc., H2 2016 236
Alzheimer's Disease - Pipeline by Glialogix, Inc., H2 2016 237
Alzheimer's Disease - Pipeline by Golden Biotechnology Corp., H2 2016 238
Alzheimer's Disease - Pipeline by Grifols, S.A., H2 2016 239
Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016 240
Alzheimer's Disease - Pipeline by Heptares Therapeutics Limited, H2 2016 241
Alzheimer's Disease - Pipeline by HitGen LTD, H2 2016 242
Alzheimer's Disease - Pipeline by Humanetics Corporation, H2 2016 243
Alzheimer's Disease - Pipeline by Ichor Medical Systems, Inc., H2 2016 244
Alzheimer's Disease - Pipeline by Icure Pharmaceutical Inc., H2 2016 245
Alzheimer's Disease - Pipeline by Immungenetics AG, H2 2016 246
Alzheimer's Disease - Pipeline by Impel NeuroPharma, Inc., H2 2016 247
Alzheimer's Disease - Pipeline by ImStar Therapeutics Inc., H2 2016 248
Alzheimer's Disease - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 249
Alzheimer's Disease - Pipeline by IntelGenx Corp., H2 2016 250
List of Figures
Number of Products under Development for Alzheimer's Disease, H2 2016 76
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H2 2016 77
Number of Products under Development by Companies, H2 2016 78
Number of Products under Investigation by Universities/Institutes, H2 2016 99
Comparative Analysis by Late Stage Development, H2 2016 106
Comparative Analysis by Clinical Stage Development, H2 2016 107
Comparative Analysis by Early Stage Products, H2 2016 108
Assessment by Monotherapy Products, H2 2016 378
Assessment by Combination Products, H2 2016 379
Number of Products by Top 10 Targets, H2 2016 380
Number of Products by Stage and Top 10 Targets, H2 2016 380
Number of Products by Top 10 Mechanism of Actions, H2 2016 404
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 404
Number of Products by Top 10 Routes of Administration, H2 2016 430
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 430
Number of Products by Top 10 Molecule Types, H2 2016 432
Number of Products by Stage and Top 10 Molecule Types, H2 2016 432
